Literature DB >> 25531677

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

Frances Stringer1, Joost DeJongh, Kazuaki Enya, Emiko Koumura, Meindert Danhof, Kohei Kaku.   

Abstract

BACKGROUND: This study applied a pharmacodynamic model-based approach to evaluate the long-term durability and glycemic control of pioglitazone in comparison with other oral glucose-lowering drugs in Japanese type 2 diabetes mellitus (T2DM) patients. SUBJECTS AND METHODS: Japanese T2DM patients were enrolled in a prospective, randomized, open-label, blinded-end point study and received pioglitazone with or without other oral glucose-lowering drugs (excluding another thiazolidinedione [TZD]) (n=293) or oral glucose-lowering drugs excluding TZD (n=294). Treatment was adjusted to achieve glycosylated hemoglobin (HbA1c) <6.9%, and samples for fasting plasma glucose (FPG) and HbA1c were collected over 2.5-4 years. A simultaneous cascading indirect response model structure was applied to describe the time course of FPG and HbA1c. HbA1c levels were described using both an FPG-dependent and an FPG-independent function. To account for titration, drug effects for both treatment groups were implemented using a time-dependent Emax model.
RESULTS: Pioglitazone was superior in both time to maximum effect and the magnitude of reduction achieved in FPG and HbA1c. A greater reduction in median FPG (-21 mg/dL vs. -9 mg/dL) was observed with pioglitazone (P<0.05). Maximum drug effect for FPG was predicted to occur earlier (11 months) for pioglitazone than for the control group (14 months). The simulated additional reduction in FPG and HbA1c achieved with pioglitazone was predicted to be maintained beyond the currently observed study duration.
CONCLUSIONS: Pioglitazone was found to result in improved glycemic control and durability compared with control treatment. This model-based approach enabled the quantification of differences in FPG and HbA1c for both treatment groups and simulation to evaluate longer-term durability on FPG and HbA1c.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531677      PMCID: PMC4346657          DOI: 10.1089/dia.2014.0222

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  35 in total

1.  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Authors:  Willem de Winter; Joost DeJongh; Teun Post; Bart Ploeger; Richard Urquhart; Ian Moules; David Eckland; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-22       Impact factor: 2.745

2.  Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.

Authors:  Yaning Wang; A Venkatesh Bhattaram; Pravin R Jadhav; Lawrence J Lesko; Rajanikanth Madabushi; J Robert Powell; Wei Qiu; He Sun; Dong S Yim; Jenny J Zheng; Jogarao V S Gobburu
Journal:  J Clin Pharmacol       Date:  2008-02       Impact factor: 3.126

Review 3.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

Authors:  Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

4.  Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.

Authors:  Shashank Rohatagi; Timothy J Carrothers; Jinyan Jin; William J Jusko; Tatiana Khariton; Joseph Walker; Kenneth Truitt; Daniel E Salazar
Journal:  J Clin Pharmacol       Date:  2008-10-20       Impact factor: 3.126

5.  Semiparametric distributions with estimated shape parameters.

Authors:  Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

6.  A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.

Authors:  Justin J Wilkins; Michel Dubar; Bernard Sébastien; Christian Laveille
Journal:  J Clin Pharmacol       Date:  2013-10-19       Impact factor: 3.126

7.  Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes.

Authors:  Andrew J Farmer; Rafael Perera; Alison Ward; Carl Heneghan; Jason Oke; Anthony H Barnett; Mayer B Davidson; Bruno Guerci; Vivien Coates; Ulrich Schwedes; Simon O'Malley
Journal:  BMJ       Date:  2012-02-27

8.  Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.

Authors:  Kohei Kaku; Hiroyuki Daida; Atsunori Kashiwagi; Akira Yamashina; Tsutomu Yamazaki; Shin-ichi Momomura; Takashi Iwase; Yoshimitsu Yamasaki; Kazuyuki Nagatsuka; Kazuo Kitagawa; Ryuzo Kawamori
Journal:  Curr Med Res Opin       Date:  2009-12       Impact factor: 2.580

Review 9.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

Authors:  S E Kahn
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122

Review 10.  Diabetes in Japan: a review of disease burden and approaches to treatment.

Authors:  Susan E Neville; Kristina S Boye; William S Montgomery; Kazuya Iwamoto; Masato Okamura; Risa P Hayes
Journal:  Diabetes Metab Res Rev       Date:  2009-11       Impact factor: 4.876

View more
  3 in total

1.  Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.

Authors:  Hiroyuki Inoue; Yoko Tamaki; Yushi Kashihara; Shota Muraki; Makoto Kakara; Takeshi Hirota; Ichiro Ieiri
Journal:  Br J Clin Pharmacol       Date:  2018-12-06       Impact factor: 4.335

2.  Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines.

Authors:  Soroush Mohammadi Jouabadi; Mitra Nekouei Shahraki; Payam Peymani; Bruno H Stricker; Fariba Ahmadizar
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

Review 3.  Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.

Authors:  Stefano Del Prato; Robert Chilton
Journal:  Diabetes Obes Metab       Date:  2017-12-21       Impact factor: 6.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.